<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537195</url>
  </required_header>
  <id_info>
    <org_study_id>124941, TrygFonden</org_study_id>
    <secondary_id>2016-051-000001, ID 1174</secondary_id>
    <nct_id>NCT04537195</nct_id>
  </id_info>
  <brief_title>Effects of a Lay-led Anxiety and Depression Self-management Program for Cancer Patients</brief_title>
  <acronym>ADSMP-C</acronym>
  <official_title>Effects on Anxiety and Depression of a Lay-led Transdiagnostic Self-management Program (ADSMP-C) for Patients Recently Treated for Cancer With Curative Intent: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TrygFonden, Denmark</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Komiteen for Sundhedsoplysning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate a peer-to-peer patient self-management program targeting&#xD;
      symptoms of anxiety and depression in a randomized trial. A total of 234 cancer patients&#xD;
      recently having completed primary treatment with curative intent in central Region Denmark&#xD;
      will be included. The intervention is a lay-led, group-based transdiagnostic patient&#xD;
      education program consisting of seven 2 ½ hour weekly sessions focusing on increasing patient&#xD;
      self-efficacy in symptom management of anxiety and depression. The intervention is highly&#xD;
      structured and manualized.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent evidence suggest that transdiagnostic interventions may be just as effective as&#xD;
      traditional diagnosis specific interventions when treating symptoms of depression and&#xD;
      anxiety. Brief lay-led transdiagnostic self-management interventions may therefore offer an&#xD;
      efficient alternative to traditional symptom specific interventions (e.g. CBT) when targeting&#xD;
      symptoms of depression and anxiety in cancer.&#xD;
&#xD;
      The present study aim to evaluate The Anxiety and Depression Symptom Management Program&#xD;
      (ADSMP) in a cancer setting (ADSMP-C). The ADSMP is a Danish adaptation of The Stanford&#xD;
      University Chronic Disease Self-Management Program (CDSMP) and is developed by the Danish&#xD;
      Health Information Committee (In Danish: Komiteen for Sundhedsoplysning in collaboration with&#xD;
      The Expert Patient Program Community Interest Company (EPPCIC), the English Health Service&#xD;
      (NHS) and Stanford University.&#xD;
&#xD;
      The ADSMP-C is a lay-led, group-based transdiagnostic patient education program consisting of&#xD;
      seven 2 ½ hour weekly sessions focusing on increasing patient self-efficacy in symptom&#xD;
      management of anxiety and depression concluded with a networking session. The intervention is&#xD;
      highly structured and manualized. Sub-group analyses on participants with a history of cancer&#xD;
      in a larger trial of ADSMP conducted by members of the study group on behalf of the Danish&#xD;
      National Board of Health showed promising results. However, a larger study is needed to&#xD;
      establish sound scientific evidence on the effectiveness of the program in a cancer setting.&#xD;
&#xD;
      A total 234 cancer patients recently having completed primary treatment with curative intent&#xD;
      in central Region Denmark will be randomized (2:1) to ADSMP-C or a control arm respectively.&#xD;
      As a part of the recruitment procedure patients will be screened with The&#xD;
      &quot;Distress-Thermometer&quot; at the departments of oncology at the two largest hospitals in Central&#xD;
      Region, Denmark following primary treatment or at a follow-up (&lt; 1yrs. after primary&#xD;
      treatment).&#xD;
&#xD;
      Participants completes online questionnaires (REDCap) at baseline (pre-randomization), at&#xD;
      post-intervention, and at three (primary follow-up) and six months post-intervention,&#xD;
      including the Beck's Depression Inventory (BDI-II) and Spielbergers State-Trait Anxiety&#xD;
      Inventory (STAI-state) (primary outcomes). In addition, all participants will be interviewed&#xD;
      at 7 month post-intervention. Outcome assessors, blind to group allocation, will perform&#xD;
      observer-based Hamilton A6 and D6 short-form ratings at the interview (secondary outcomes).&#xD;
&#xD;
      Data will be evaluated by mixed-effects regression analyses (intention-to-treat).&#xD;
&#xD;
      The current study will be the first to evaluate the efficacy of ADSMP in a cancer setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Assessors will be blinded at 7-month follow-up when administering the Hamilton rating scales (secondary outcomes). Participants will be instructed not to disclose their group allocation until the interview is completed</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Depressive Symptoms</measure>
    <time_frame>Baseline and 3 months post-intervention</time_frame>
    <description>Beck Depression Inventory (BDI-II)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Anxiety Symptoms</measure>
    <time_frame>Baseline and 3 months post-intervention</time_frame>
    <description>Spielberger State-Trait Inventory (STAI). State subscale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Anxiety Symptoms</measure>
    <time_frame>Baseline and 6 months post-intervention</time_frame>
    <description>Spielberger State-Trait Inventory (STAI). State subscale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depressive Symptoms</measure>
    <time_frame>Baseline and 6 months post-intervention</time_frame>
    <description>Beck Depression Inventory (BDI-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anxiety (observer-rated)</measure>
    <time_frame>Baseline and 7 months post-intervention</time_frame>
    <description>Hamilton Anxiety Rating Scale (HAM-A6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depression (observer-rated)</measure>
    <time_frame>Baseline and 7 months post-intervention</time_frame>
    <description>Hamilton Depression Rating Scale (HAM-D6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fear of cancer recurrence</measure>
    <time_frame>Baseline and 3 months post-intervention</time_frame>
    <description>Concerns About Recurrence Questionaire (CARQ-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-efficacy - Personal control</measure>
    <time_frame>Baseline and 3 months post-intervention</time_frame>
    <description>The Revised Illness Perception Questionnaire (IPQ-R). Personal Control subscale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-efficacy - Social support</measure>
    <time_frame>Baseline, and 3 months post-intervention</time_frame>
    <description>Obtain Help from Community, Family, Friends Scale (SECD-Ssup)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Neoplasms</condition>
  <condition>Anxiety</condition>
  <condition>Self Efficacy</condition>
  <condition>Psychological Distress</condition>
  <condition>Cancer</condition>
  <condition>Distress, Emotional</condition>
  <condition>Depression</condition>
  <condition>Group, Peer</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADSMP-C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Wait-list control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ADSMP-C</intervention_name>
    <description>A transdiagnostic, lay-led, group-based self-management program consisting of seven 2 ½ hour weekly sessions focusing on increasing patient self-efficacy in symptom management of anxiety and depression in cancer (ADSMP-C)</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treated in Central Region Denmark&#xD;
&#xD;
          -  Recently completed (&lt; 1 yr.) primary treatment for cancer with curative intent&#xD;
&#xD;
          -  BDI-II score &gt;=14 and/or STAI-state score &gt;=40&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not sufficient Danish language skills to fill Questionnaires and participate in a&#xD;
             group based intervention&#xD;
&#xD;
          -  Psychosis&#xD;
&#xD;
          -  Aggressive behavior&#xD;
&#xD;
          -  Imminent suicidal risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soren Christensen, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. Psychology, Aarhus University, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soren Christensen, MSc.</last_name>
    <phone>(+45) 8716 5876</phone>
    <email>sc@psy.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dep. Oncology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders B Jensen, MD, PhD</last_name>
      <email>Anders.Bonde.Jensen@auh.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Anders B Jensen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dep. Oncology, Regional Hospital West Jutland</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halla O Skuladottir, PhD, DMSc</last_name>
      <phone>(+45) 78437400</phone>
      <email>hallskul@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Halla O Skuladottir, PhD, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intervention</keyword>
  <keyword>RCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>At the present the policy of Aarhus University does not allow the sharing of data according to GDPR rules. However this policy may be subject to change</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

